Novartis AG to Discuss Acquisition of Xiidra® from Takeda Pharmaceutical Co Ltd Call Transcript
Good morning and good afternoon and welcome to Novartis investor call and webcast on the proposed Xiidra acquisition. (Operator Instructions) And the conference is being recorded. (Operator Instructions) A recording of the conference call including the Q&A session will be available on our website shortly after the call ends. (Operator Instructions) And with that, I would now like to hand over the conference to Mr. Samir Shah, Global Head of Investor Relations. Please go ahead, sir.
Thank you very much, and good morning and good afternoon, everybody. And thanks for your time yet again to join us on our investor call today. So with us, we have Paul Hudson, CEO of Novartis Pharmaceuticals; Dirk Sauer, who's head of the global franchise from a development perspective for ophthalmology; and Patrick Mooney, who's the U.S. franchise head for ophthalmology from a commercial perspective.
Before I hand across to Paul, I'd just like to read you the safe harbor statement. The information presented today contains
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
